Speedy listing of Iressa's insurance price urged

Published: 2004-01-30 06:59:00

Updated: 2004-01-30 06:59:00

In a recent meeting with the local Health World Network over the pending health insurance price of Iressa, an anticancer agent, AstraZeneca Korea said that the government is still in the process of assessing its reimbursement price level, which has been delayed for more than two months, noting th...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK